Addex Therapeutics Ltd (ADXN.SW)
CHF 0.06
(-8.5%)
CHF 0.06
(-8.5%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.14 CHF | 70.21% |
| 2022 | -0.47 CHF | -4.44% |
| 2021 | -0.45 CHF | 6.25% |
| 2020 | -0.48 CHF | 14.29% |
| 2019 | -0.56 CHF | -693.2% |
| 2018 | -0.07 CHF | 71.76% |
| 2017 | -0.25 CHF | 10.71% |
| 2016 | -0.28 CHF | 28.21% |
| 2015 | -0.39 CHF | -116.67% |
| 2014 | -0.18 CHF | 88.75% |
| 2013 | -1.60 CHF | 53.08% |
| 2012 | -3.41 CHF | 18.62% |
| 2011 | -4.19 CHF | 26.36% |
| 2010 | -5.69 CHF | 23.52% |
| 2009 | -7.44 CHF | -93.25% |
| 2008 | -3.85 CHF | 44.92% |
| 2007 | -6.99 CHF | 2.78% |
| 2006 | -7.19 CHF | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.03 CHF | -5.67% |
| 2024 Q2 | 0.13 CHF | 510.09% |
| 2023 FY | - CHF | 70.21% |
| 2023 Q4 | -0.03 CHF | 11.5% |
| 2023 Q3 | -0.03 CHF | 8.63% |
| 2023 Q2 | -0.04 CHF | 6.55% |
| 2023 Q1 | -0.04 CHF | 53.07% |
| 2022 Q1 | -0.16 CHF | -23.08% |
| 2022 Q3 | -0.08 CHF | 57.65% |
| 2022 FY | - CHF | -4.44% |
| 2022 Q2 | -0.20 CHF | -25.0% |
| 2022 Q4 | -0.08 CHF | 0.12% |
| 2021 Q1 | -0.08 CHF | 1.13% |
| 2021 FY | - CHF | 6.25% |
| 2021 Q2 | -0.14 CHF | -77.89% |
| 2021 Q3 | -0.11 CHF | 21.43% |
| 2021 Q4 | -0.13 CHF | -18.18% |
| 2020 FY | - CHF | 14.29% |
| 2020 Q4 | -0.08 CHF | 33.67% |
| 2020 Q3 | -0.12 CHF | 0.0% |
| 2020 Q2 | -0.12 CHF | 25.0% |
| 2020 Q1 | -0.16 CHF | -14.29% |
| 2019 Q3 | -0.14 CHF | 17.65% |
| 2019 Q1 | -0.12 CHF | -59.79% |
| 2019 FY | - CHF | -693.2% |
| 2019 Q4 | -0.14 CHF | 0.0% |
| 2019 Q2 | -0.17 CHF | -41.67% |
| 2018 FY | - CHF | 71.76% |
| 2018 Q3 | -0.08 CHF | -226.64% |
| 2018 Q2 | 0.06 CHF | 18.6% |
| 2018 Q1 | 0.05 CHF | 187.41% |
| 2018 Q4 | -0.08 CHF | 0.0% |
| 2017 Q3 | -0.06 CHF | 20.0% |
| 2017 FY | - CHF | 10.71% |
| 2017 Q4 | -0.06 CHF | 0.0% |
| 2017 Q2 | -0.07 CHF | 0.0% |
| 2017 Q1 | -0.07 CHF | -0.85% |
| 2016 Q1 | -0.07 CHF | -4.69% |
| 2016 FY | - CHF | 28.21% |
| 2016 Q4 | -0.07 CHF | 0.0% |
| 2016 Q3 | -0.07 CHF | -28.91% |
| 2016 Q2 | -0.06 CHF | 17.91% |
| 2015 Q4 | -0.06 CHF | 0.0% |
| 2015 Q2 | -0.13 CHF | 0.0% |
| 2015 Q1 | -0.13 CHF | -227.46% |
| 2015 FY | - CHF | -116.67% |
| 2015 Q3 | -0.06 CHF | 50.77% |
| 2014 Q1 | -0.05 CHF | -78.62% |
| 2014 Q4 | -0.04 CHF | 0.0% |
| 2014 Q3 | -0.04 CHF | 20.6% |
| 2014 Q2 | -0.05 CHF | -1.42% |
| 2014 FY | - CHF | 88.75% |
| 2013 Q3 | -0.03 CHF | 96.55% |
| 2013 Q4 | -0.03 CHF | 0.0% |
| 2013 FY | - CHF | 53.08% |
| 2013 Q1 | -0.81 CHF | -12.5% |
| 2013 Q2 | -0.80 CHF | 1.23% |
| 2012 Q3 | -0.72 CHF | 0.0% |
| 2012 FY | - CHF | 18.62% |
| 2012 Q4 | -0.72 CHF | 0.0% |
| 2011 FY | - CHF | 26.36% |
| 2010 FY | - CHF | 23.52% |
| 2009 FY | - CHF | -93.25% |
| 2008 FY | - CHF | 44.92% |
| 2007 FY | - CHF | 2.78% |
| 2006 FY | - CHF | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| BB Biotech AG | -3.77 CHF | 96.286% |
| Basilea Pharmaceutica AG | 0.87 CHF | 116.092% |
| Evolva Holding SA | -19.50 CHF | 99.282% |
| Idorsia Ltd | -1.67 CHF | 91.617% |
| Kuros Biosciences AG | -0.38 CHF | 63.158% |
| Molecular Partners AG | -1.89 CHF | 92.593% |
| Relief Therapeutics Holding AG | -8.35 CHF | 98.323% |
| Santhera Pharmaceuticals Holding AG | 5.18 CHF | 102.703% |